NCT05447897

Brief Summary

Tobacco use is the leading preventable cause of death in the US and a major driver of health disparities. Among our tools for reducing the harms of tobacco is lung cancer screening (LCS). This study will combine a review of existing qualitative and quantitative data on barriers to lung cancer screening and smoking cessation in underserved populations, a quantitative analysis of predictors of lung cancer screening and smoking cessation treatment use among Massachusetts Federally Qualified Health Centers (FQHC)s, and a stakeholder advisory group to synthesize these data and select implementation strategies that reflects the critical determinants and the strengths and resource constraints of the Federally Qualified Health Centers (FQHC) context.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 29, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 7, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

December 1, 2022

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2023

Completed
11 months until next milestone

Results Posted

Study results publicly available

April 16, 2024

Completed
Last Updated

April 16, 2024

Status Verified

March 1, 2024

Enrollment Period

6 months

First QC Date

June 29, 2022

Results QC Date

February 29, 2024

Last Update Submit

March 19, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Feasibility of Intervention Measure

    Feasibility of Intervention Measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes

    End of study, up to 16 weeks

Secondary Outcomes (2)

  • Acceptability of Intervention Measure

    End of study, up to 16 weeks

  • Intervention Appropriateness Measure

    End of study, up to 16 weeks

Study Arms (1)

Stakeholder Advisory Group

OTHER

To co-design an implementation strategy that targets critical components in the delivery of SCT or LCS services for patients who smoke. Convene a stakeholder advisory group (CHC providers, quality improvement specialists, community engagement staff, and specialty providers) to review the results of the literature review and quantitative analysis of deidentified data in order to select a set of implementation strategies from a menu of strategies to implement. The team will meet with the stakeholder advisory group four times for 1-2 hours each.

Other: Qualitative Group InterviewsOther: Stakeholder advisory group

Interventions

One time interview, 60-90 minutes

Stakeholder Advisory Group

The team will meet with the stakeholder advisory group four times for 1-2 hours each

Stakeholder Advisory Group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • FQHC implementation team including staff in the intervention FQHCs and their lung screening partners

You may not qualify if:

  • FQHC staff or partners who leave the organization before end of study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massacusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

MeSH Terms

Conditions

Smoking Cessation

Condition Hierarchy (Ancestors)

Health BehaviorBehavior

Results Point of Contact

Title
Dr. Gina Kruse, PI
Organization
General Internal Medicine, University of Colorado School of

Study Officials

  • Gina Kruse, MD, MPH

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 29, 2022

First Posted

July 7, 2022

Study Start

December 1, 2022

Primary Completion

May 31, 2023

Study Completion

May 31, 2023

Last Updated

April 16, 2024

Results First Posted

April 16, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will share

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Data can be shared no earlier than 1 year following the date of publication
Access Criteria
Contact the Partners Innovations team at http://www.partners.org/innovation

Locations